Overview Dividends

(RVMD) Revolution Medicines - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76155X1000

RAS Inhibitors, Companion Inhibitors, Clinical Pipeline, Targeted Therapy

RVMD EPS (Earnings per Share)

EPS (Earnings per Share) of RVMD over the last years for every Quarter: "2020-09": -0.42, "2020-12": -0.52, "2021-03": -0.53, "2021-06": -0.6, "2021-09": -0.72, "2021-12": -0.71, "2022-03": -0.78, "2022-06": -0.82, "2022-09": -0.87, "2022-12": -0.63, "2023-03": -0.72, "2023-06": -0.92, "2023-09": -0.99, "2023-12": -1.14, "2024-03": -0.7, "2024-06": -0.81, "2024-09": -0.94, "2024-12": -1.12, "2025-03": -1.13, "2025-06": -1.31, "2025-09": -1.61,
EPS Growth (3Y CAGR): -58.40%
EPS Trend (3Y Correlation): -79.5%

RVMD Revenue

Revenue of RVMD over the last years for every Quarter: 2020-09: 12.661, 2020-12: 8.751, 2021-03: 10.131, 2021-06: 8.698, 2021-09: 1.101, 2021-12: 9.46, 2022-03: 7.578, 2022-06: 9.116, 2022-09: 3.356, 2022-12: 15.33, 2023-03: 7.014, 2023-06: 3.824, 2023-09: 0, 2023-12: 0.742, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 261.592, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Revenue Growth (3Y CAGR): -15.44%
Revenue Trend (3Y Correlation): -29.5%
Risk via 10d forecast
Volatility 49.5%
Value at Risk 5%th 72.6%
Relative Tail Risk -10.83%
Reward TTM
Sharpe Ratio 0.47
Alpha -0.59
Character TTM
Hurst Exponent 0.334
Beta 1.086
Beta Downside 0.982
Drawdowns 3y
Max DD 48.63%
Mean DD 18.80%
Median DD 15.89%

Description: RVMD Revolution Medicines November 04, 2025

Revolution Medicines (NASDAQ:RVMD) is a clinical-stage precision-oncology firm that concentrates on “RAS-ON” inhibitors-molecules that bind active RAS variants-to treat cancers driven by mutant RAS signaling. Its pipeline includes three Phase 1 monotherapy candidates (daraxonrasib RMC-6236, elironrasib RMC-6291, and zoldonrasib RMC-9805) and a suite of “RAS companion” agents such as the SOS1 inhibitor RMC-5845 and the selective mTORC1 inhibitor RMC-5552, the latter in Phase 1 and the former in Phase 2. The company’s strategy is to pair these agents with each other or with external therapies to achieve durable tumor suppression.

Key external data points that shape RVMD’s outlook: (1) As of the latest 10-Q, the company reported ~ $210 million in cash and equivalents, giving it runway through late 2026 at current burn rates (~$55 million per quarter). (2) Early Phase 1 data for daraxonrasib showed a 45 % disease-control rate in KRAS-mutant non-small-cell lung cancer, suggesting potential differentiation from competing KRAS-G12C inhibitors. (3) The global market for RAS-targeted therapies is projected to expand at a CAGR of roughly 15 % from 2024-2030, driven by increasing molecular-diagnostic adoption and unmet need in KRAS-mutant tumors.

For a deeper, data-driven assessment of RVMD’s valuation and risk profile, you might explore the analyst tools on ValueRay to see how these fundamentals compare with sector peers.

RVMD Stock Overview

Market Cap in USD 12,446m
Sub-Industry Biotechnology
IPO / Inception 2020-02-13
Return 12m vs S&P 500 3.03%
Analyst Rating 4.67 of 5

RVMD Dividends

Currently no dividends paid

RVMD Growth Ratios

CAGR 3y 49.73%
CAGR/Max DD Calmar Ratio 1.02
CAGR/Mean DD Pain Ratio 2.65
Current Volume 3958.5k
Average Volume 2378.3k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-961.0m TTM) > 0 and > 6% of Revenue (6% = 15.7m TTM)
FCFTA -0.35 (>2.0%) and ΔFCFTA -3.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 662.0% (prev 197.9k%; Δ -197.2kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.34 (>3.0%) and CFO -761.8m > Net Income -961.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (189.2m) change vs 12m ago 13.42% (target <= -2.0% for YES)
Gross Margin -52.01% (prev -56.4k%; Δ 56.3kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 13.03% (prev 0.04%; Δ 12.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -83.31 (EBITDA TTM -1.01b / Interest Expense TTM 12.3m) >= 6 (WARN >= 3)

Altman Z'' -6.03

(A) 0.77 = (Total Current Assets 1.98b - Total Current Liabilities 245.6m) / Total Assets 2.25b
(B) -1.11 = Retained Earnings (Balance) -2.50b / Total Assets 2.25b
warn (B) unusual magnitude: -1.11 — check mapping/units
(C) -0.51 = EBIT TTM -1.03b / Avg Total Assets 2.01b
(D) -3.82 = Book Value of Equity -2.50b / Total Liabilities 655.0m
Total Rating: -6.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.16

1. Piotroski 0.0pt = -5.0
2. FCF Yield -7.28% = -3.64
3. FCF Margin data missing
4. Debt/Equity 0.10 = 2.50
5. Debt/Ebitda 0.06 = 2.50
6. ROIC - WACC (= -62.56)% = -12.50
7. RoE -49.25% = -2.50
8. Rev. Trend -29.48% = -2.21
9. EPS Trend -79.54% = -3.98

What is the price of RVMD shares?

As of November 16, 2025, the stock is trading at USD 67.75 with a total of 3,958,489 shares traded.
Over the past week, the price has changed by +11.05%, over one month by +42.63%, over three months by +88.09% and over the past year by +18.09%.

Is Revolution Medicines a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Revolution Medicines (NASDAQ:RVMD) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 25.16 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RVMD is around 69.00 USD . This means that RVMD is currently overvalued and has a potential downside of 1.85%.

Is RVMD a buy, sell or hold?

Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RVMD price?

Issuer Target Up/Down from current
Wallstreet Target Price 81 19.5%
Analysts Target Price 81 19.5%
ValueRay Target Price 78 15.1%

RVMD Fundamental Data Overview November 15, 2025

Market Cap USD = 12.45b (12.45b USD * 1.0 USD.USD)
P/S = 9035.0954
P/B = 7.9693
Beta = 0.989
Revenue TTM = 261.6m USD
EBIT TTM = -1.03b USD
EBITDA TTM = -1.01b USD
Long Term Debt = 158.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.3m USD (from shortTermDebt, last quarter)
Debt = 158.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.0m USD (from netDebt column, last quarter)
Enterprise Value = 10.67b USD (12.45b + Debt 158.5m - CCE 1.93b)
Interest Coverage Ratio = -83.31 (Ebit TTM -1.03b / Interest Expense TTM 12.3m)
FCF Yield = -7.28% (FCF TTM -777.1m / Enterprise Value 10.67b)
FCF Margin = -297.1% (FCF TTM -777.1m / Revenue TTM 261.6m)
Net Margin = -367.4% (Net Income TTM -961.0m / Revenue TTM 261.6m)
Gross Margin = -52.01% ((Revenue TTM 261.6m - Cost of Revenue TTM 397.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.74 (Enterprise Value 10.67b / Total Assets 2.25b)
Interest Expense / Debt = 7.21% (Interest Expense 11.4m / Debt 158.5m)
Taxrate = 0.13% (-753.0k / -600.8m)
NOPAT = -1.03b (EBIT -1.03b * (1 - 0.13%)) [loss with tax shield]
Current Ratio = 8.05 (Total Current Assets 1.98b / Total Current Liabilities 245.6m)
Debt / Equity = 0.10 (Debt 158.5m / totalStockholderEquity, last quarter 1.60b)
Debt / EBITDA = 0.06 (negative EBITDA) (Net Debt -59.0m / EBITDA -1.01b)
Debt / FCF = 0.08 (negative FCF - burning cash) (Net Debt -59.0m / FCF TTM -777.1m)
Total Stockholder Equity = 1.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -42.67% (Net Income -961.0m / Total Assets 2.25b)
RoE = -49.25% (Net Income TTM -961.0m / Total Stockholder Equity 1.95b)
RoCE = -48.68% (EBIT -1.03b / Capital Employed (Equity 1.95b + L.T.Debt 158.5m))
RoIC = -52.56% (negative operating profit) (NOPAT -1.03b / Invested Capital 1.95b)
WACC = 9.99% (E(12.45b)/V(12.60b) * Re(10.03%) + D(158.5m)/V(12.60b) * Rd(7.21%) * (1-Tc(0.00)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.77%
Fair Price DCF = unknown (Cash Flow -777.1m)
EPS Correlation: -79.54 | EPS CAGR: -58.40% | SUE: -1.35 | # QB: 0
Revenue Correlation: -29.48 | Revenue CAGR: -15.44% | SUE: -0.17 | # QB: 0

Additional Sources for RVMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle